
    
      Hypothesis: Mirabegron is effective in reducing symptoms in women with pain related urinary
      frequency and urgency.

      Specific Aims:

        1. To measure the efficacy of Mirabegron in the treatment of frequency and urgency, using
           voiding diaries.

        2. To measure the number of patients with a 50% or greater reduction in frequency and
           urgency, using voiding diaries.

        3. To measure the number of patients with a 50% or greater reduction in bladder pain as
           measured in the O'Leary-Sant (OLS) IC symptom and problem, and the Lowell Parsons Pelvic
           Pain and Urgency/Frequency (PUF) patient symptom scale.

      Intervention/Project goal: Treatment with Mirabegron 25mg for 4 weeks with an option for dose
      escalation to 50mg. Duration of study 12 weeks.

      Inclusion criteria: Women between the ages of 18 and 89 with complaints of pain related
      urinary frequency are eligible to participate in the study.

      Exclusion criteria:

      Patients will be excluded from the study if they have:

        1. Severe Liver disease, Child-Pugh class c

        2. Severe Kidney disease, GFR<30

        3. Elevated blood pressure > 160/95 (in package insert bp >180/110)

        4. Urinary retention

        5. Pregnant, will become pregnant, or are nursing

        6. History of recurrent urinary tract infection

        7. Tachycardia: pulse > 100

        8. Presently on study drug mirabegron; patient must be willing to participate in a 30 day
           washout period to be eligible for inclusion

        9. Medications - metoprolol, desipramine, digoxin, propafenone, thioridazine, flecainide,
           warfarin
    
  